Photodynamic Diagnosis in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Cumulative Analysis of Prospective Studies

European Urology

Volumn 57, Issue 4, 2010, Pages 595-606

  Kausch, Ingo ^a   Sommerauer, Martin ^a   Montorsi, Francesco ^b   Stenzl, Arnulf ^c   Jacqmin, Didier ^d   Jichlinski, Patrice ^e   Jocham, Dieter ^a   Ziegler, Andreas ^a   Vonthein, Reinhard ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

5 ALA; 5 aminolevulinic acid; Bladder cancer; Bladder neoplasms; HAL; Hexaminolevulinate; Meta analysis; PDD; Transurethral resection; TUR

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER;

BLADDER CANCER; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HUMAN; INTERMETHOD COMPARISON; PHOTODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; REVIEW; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

AMINOLEVULINIC ACID; CYSTECTOMY; CYSTOSCOPY; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 77249090657     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.11.041     Document Type: Review

References (63)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 58 (2008) 71-96
2. European Cancer Observatory. International Agency for Research on Cancer Web site. http://eu-cancer.iarc.fr. Updated March 16, 2009.
3. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
4. Jichlinski P., and Leisinger H.J. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist!. Urol Int 74 (2005) 97-101
5. Krieg R.C., Fickweiler S., Wolfbeis O.S., and Knuechel R. Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro. Photochem Photobiol 72 (2000) 226-233
6. Jocham D., Stepp H., and Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol 53 (2008) 1138-1150
7. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.0.0 [updated February 2008]. Cochrane Collaboration Web site. http://cochrane.org/resources/handbook/.
8. Moher D., Schulz K.F., and Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134 (2001) 657-662
9. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 326 (2003) 41-44
10. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
11. Schwarzer G. meta: an R package for meta-analysis. R News 7 (2007) 40-45
12. Nordic Cochrane Centre, ed. Review Manager (RevMan) version 5.0. Copenhagen, Denmark: Cochrane Collaboration; 2008.
13. Jichlinski P., Guillou L., Karlsen S.J., et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 170 (2003) 226-229
14. Babjuk M., Soukup V., Petrik R., et al. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 96 (2005) 798-802
15. Danil'chenko D., Riedl C., Koenig F., et al. The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer. Aktuelle Urol 35 (2004) 497-501
16. Danil'chenko D.I., Riedl C.R., Sachs M.D., et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174 (2005) 2129-2133
17. Denzinger S., Burger M., Walter B., et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69 (2007) 675-679
18. Denzinger S., Wieland W.F., Otto W., et al. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 101 (2008) 566-569
19. Filbeck T., Pichlmeier U., Knuechel R., et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumours. J Urol 168 (2002) 67-71
20. Filbeck T., Pichlmeier U., Knuechel R., et al. Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence [in German]. Urologe A 42 (2003) 1366-1373
21. Kriegmair M., Zaak D., Rothenberger K.H., et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168 (2002) 475-478
22. Riedl C.R., Danil'chenko D., Koenig F., et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 165 (2001) 1121-1123
23. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174 (2005) 862-866
24. Filbeck T., Pichlmeier U., Knuechel R., et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma?. Urology 60 (2002) 1025-1028
25. Colombo R., Naspro R., Bellinzoni P., et al. Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder. Ther Clin Risk Manag 3 (2007) 1003-1007
26. Fradet Y., Grossman H.B., Gomella L., et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 178 (2007) 68-73
27. Grossman H.B., Gomella L., Fradet Y., et al. A phase III multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178 (2007) 62-67
28. Loidl W., Schmidbauer J., Susani M., and Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?. Eur Urol 47 (2005) 323-326
29. Schmidbauer J., Witjes F., Schmeller N., Donat R., Susani M., Marberger M., and Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 171 (2004) 135-138
30. Witjes J.A., Moonen P.M.J., and van der Heijden A.G. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study. Eur Urol 47 (2005) 319-322
31. Alken P., Siegsmund M., Gromoll-Bergmann K., et al. A randomised controlled multicentre trial to compare the effects of transurethral detection and resection of bladder carcinomas under 5-ALA induced fluorescence light to conventional white light [abstract 593]. Eur Urol Suppl 6 (2007) 171
32. Penkoff H., Steiner H., Dajc-Sommerer E., et al. Transurethral detection and resection of bladder carcinomas under white or 5-ALA induced fluorescence light: results of the first double-blind placebo-controlled clinical trial [abstract 1085]. J Urol 177 Suppl 4 (2007) 358
33. Babjuk M., Soukup V., Petrik R., et al. Fluorescence cystoscopy in the diagnostics and treatment of superficial urinary bladder tumours [in Czech]. Cas Lek Cesk 144 Suppl 2 (2005) 15-18
34. Burger M., Zaak D., Stief C.G., et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 52 (2007) 142-147
35. Danil'chenko D.I., Koenig F., Riedl K., et al. Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-induced fluorescence in transurethral resection of non-invasive bladder cancer [in Russian]. Voprosy Onkologii 49 (2003) 734-737
36. Filbeck T., Roessler W., Knuechel R., et al. 5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumours. Urology 53 (1999) 77-81
37. Ray E.R., Chatterton K., Khan M.S., et al. Hexylaminolaevulinate "blue light" fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology. BJU Int 103 (2009) 1363-1367
38. ® photodynamic diagnosis following intravesical bacille Calmette Guerin treatment for superficial bladder cancer [abstract 1583]. J Urol 177 S4 (2007) 524
39. Al'-Shukri S.K.H., Danil'chenko D.I., König F., and Shnorr D. ALA fluorescent diagnosis of bladder cancer [in Russian]. Urologiia 5 (2000) 48-50
40. Cheng C.W., Lau W.K., Tan P.H., and Olivo M. Cystoscopic diagnosis of bladder cancer by intravesical instillation of 5-aminolevulinic acid induced porphyrin fluorescence-the Singapore experience. Ann Acad Med Singapore 29 (2000) 153-158 (in Chinese; the abstract is in English)
41. De Dominicis C., Liberti M., Perugia G., et al. Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity. Urology 57 (2001) 1059-1062
42. D'Hallewin M.A., Vanherzeele H., and Baert L. Fluorescence detection of flat transitional cell carcinoma after intravesical instillation of aminolevulinic acid. Am J Clin Oncol 21 (1998) 223-225
43. Ehsan A., Sommer F., Haupt G., and Engelmann U. Significance of fluorescence cystoscopy for diagnosis of superficial bladder cancer after intravesical instillation of delta aminolevulinic acid. Urol Int 67 (2001) 298-304
44. Filbeck T., Roessler W., Knuechel R., et al. Clinical results of the transurethral resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol 13 (1999) 117-121
45. Grimbergen M.C.M., van Swol C.F.P., Jonges T.G.N., et al. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 44 (2003) 51-56
46. Grosse J., Makris A., Durt K., and Jakse G. Does fluorescence enhanced cystoscopy and transurethral resection of bladder cancer improve the quality of resection, accuracy of staging and patients care?. Urologe 47 Suppl 1 (2008) 11.4
47. Hungerhuber E., Stepp H., Kriegmair M., et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69 (2007) 260-264
48. Inoue K., Karashima T., Kamada M., et al. Clinical experience with intravesical instillations of 5-aminolevulinic acid (5-ALA) for the photodynamic diagnosis using fluorescence cystoscopy for bladder cancer [in Japanese]. Nippon Hinyokika Gakkai Zasshi 97 (2006) 719-729
49. Jeon S.S., Kang I., Hong J.H., et al. Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms. J Endourol 15 (2001) 753-759
50. Jichlinski P., Forrer M., Mizeret J., et al. Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med 20 (1997) 402-408
51. Koenig F., McGovern F.J., Larne R., et al. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int 83 (1999) 129-135
52. Kriegmair M., Baumgartner R., Knuechel R., et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 44 (1994) 836-841
53. Kriegmair M., Baumgartner R., Knüchel R., et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 155 (1996) 105-110
54. Kriegmair M., Zaak D., Knuechel R., et al. Photodynamic cystoscopy for detection of bladder tumors. Semin Laparosc Surg 6 (1999) 100-103
55. Kriegmair M., Zaak D., Stepp H., et al. Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol 36 (1999) 386-392
56. Lopatkin N.A., Kamalov A.A., Kudriavtsev V., and Tokarev F.V. Fluorescent diagnostics of urinary bladder cancer [in Russian]. Urologiia 4 (2000) 3-6
57. Matveev B.P., Kudashev B.V., Bukharkin B.V., et al. Role of fluorescent control in raising radicality of surgical treatment for superficial bladder cancer [in Russian]. Urologiia 3 (2000) 22-24
58. Riedl C.R., Plas E., and Pfluger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid. J. Endourol 13 (1999) 755-759
59. Zaak D., Hungerhuber E., Schneede P., et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 95 (2002) 1234-1238
60. Zaak D., Kriegmaier M., Stepp H., et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid. Results of 1012 fluorescence endoscopies. Urology 57 (2001) 690-694
61. Schumacher M.C., Holmäng S., Davidsson T., et al. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-ALA under visible and fluorescent light - multicenter phase III clinical trial [abstract 1009]. Eur Urol Suppl 8 (2009) 373
62. Stenzl A.S., Roessler W.R., Fradet Y.F., et al. Hexvix® fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: a multicentre, prospective, randomized study [abstract 1010]. Eur Urol Suppl 8 (2009) 373
63. Burger M., Stief C.G., Zaak D., et al. Hexaminolaevulinate is equal to 5-aminolaevilinic acid concerning residual tumour and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumours. Urology 74 (2009) 1282-1286